The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

MD Anderson Cancer Center partners with GlaxoSmithKline

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MD ANDERSON CANCER CENTER formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing anticancer immunotherapies.

This marks the fourth and final collaboration in a plan to partner with pharmaceutical companies as part of MD Anderson’s Moon Shots Program. GSK and MD Anderson will work to identify therapeutic approaches, evaluate patient responses in clinical trials, and develop immunotherapy drugs.

YOU MAY BE INTERESTED IN

AACR Cancer Progress Report makes the case for federal investment in cancer research

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
By Sara Willa Ernst

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account